Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

According to the American Cancer Society, approximately 13,000 adults were newly diagnosed with AML in 2009 in the United States with approximately 9,000 expected to die of the disease in that year.  AML is generally a disease of older people and is uncommon before the age of 40.  The average age of a patient with AML is 67 and median survival for these patients is less than six months.  The five-year survival rate for all AML patients is less than 15 percent. According to a report from Decision Resources, the U.S. AML market is expected to more than double by 2015.

About the Ambit Biosciences/Astellas Pharma Inc. Collaboration

In December 2009, Ambit Biosciences and Astellas Pharma Inc. entered into a global strategic partnership agreement to jointly research, develop and commercialize FLT3 kinase inhibitors in multiple indications, including the lead investigational compound, quizartinib.  The companies are presently evaluating quizartinib in a Phase 2 clinical trial in relapsed and refractory AML patients that have the internal tandem duplication (ITD) mutation in the FLT3 gene.  The companies are also collaborating on a comprehensive development program to explore the utility of quizartinib in other AML patient subpopulations.  Additionally, the companies are collaborating on a research and development program for additional FLT3 inhibitors for a variety of oncology and non-oncology indications.  The companies share equal responsibility and expenses for the development of products in the U.S. and Europe, while Astellas has sole responsibility in the rest of the world.  Astellas will be responsible for implementation of commercialization activities worldwide.  Ambit received a $40 million up-front payment upon entering into the collaboration agreement, and is eligible to receive up to $350 million in development milestone payments, undi
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a ... of the Top 10 Plastic Surgeon Specialists for Nashville, TN ... His complete line includes a Hydration Booster, Retexturing Night Crème, ... and skin a younger, more radiant appearance while protecting them ... different, that is why at Dr. J. J. Wendel Plastic ...
(Date:7/28/2014)... , July 28, 2014 Sapphire Energy, ... today announced the appointment of biotechnology veteran James ... board of directors. Levine replaces Cynthia ,CJ, Warner, who ... will remain chairman of the company,s board of directors. ... Energy,s mission to deliver commercial scale algae-based fuels has ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... When semiconductor nanorods are exposed to light, ... clustering nanorods together, physicists at the University of ... is increased dramatically providing new insight into this ... by associate professor Marija Drndic,s group, including graduate ...
... June 23, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (" China-Biotics ... (NASDAQ: CHBT ), a leading developer, manufacturer, and ... 20, 2011, the Company received a letter from the NASDAQ Listing ... Company has not yet filed its Annual Report on Form 10-K ...
... Biosciences, Inc. (NASDAQ: NBIX ) announced today that ... a Notice of Allowance for the Company,s proprietary Vesicular Monoamine ... that a composition of matter patent on NBI-98854 will have ... Additionally, on June 17, 2011, the Company held a ...
Cached Biology Technology:Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 2Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 3China-Biotics, Inc. Receives NASDAQ Delisting Notification 2China-Biotics, Inc. Receives NASDAQ Delisting Notification 3Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor 2Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor 3
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
(Date:7/29/2014)... of Ascension Island, one of the world,s largest green ... Writing in the journal Biodiversity and Conservation , ... Government Conservation Department report that the number of green ... increased by more than 500 per cent since records ... are now estimated to be laid on the Island,s ...
(Date:7/29/2014)... of Kent has shown for the first time how ... that could have a major impact on cancer therapy ... uncovered the mechanism whereby the physical properties of the ... are ,fine-tuned, to undertake different functions. , While ... providing a framework for the cell, others are more ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... CA July 12, 2012 Readers of the top-ranked scientific ... noticed a recent wave of articles, most recently in the ... importance for biology and medicine. These papers, all published this ... of Professor Raymond Stevens, illuminate a large and medically important ...
... century ago, the South Pole was one of Earth,s last ... activity. Led by Monash University,s Professor Steven Chown, a ... out the current and future conservation challenges facing the Antarctic ... . The team analysed the effectiveness of the existing ...
... trying to control the invasive tamarisk plant have been ... a rapidly evolving beetle that has been changing its ... Their findings, in a paper titled "Evolution of critical ... Diorhabda carinulata , a biological control agent against ...
Cached Biology News:Large, medically important class of proteins starts to yield its secrets 2Large, medically important class of proteins starts to yield its secrets 3Large, medically important class of proteins starts to yield its secrets 4Large, medically important class of proteins starts to yield its secrets 5Large, medically important class of proteins starts to yield its secrets 6Large, medically important class of proteins starts to yield its secrets 7The challenges facing the vulnerable Antarctic 2Tamarisk biocontrol efforts get evolutionary boost 2Tamarisk biocontrol efforts get evolutionary boost 3
... Flat bottoms,• Nonreversible ... to reduce contamination,• Individual ... identification,• Uniform footprint for ... for optimal cell attachment,• ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Biology Products: